Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferric Gluconate→

Ferric Gluconate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
38658-53-6
Molecular formula
C18H33FeO21
Molecular weight
641.3 g/mol
Drug class
Intravenous ferric gluconate–carbohydrate complexparenteral iron replacement agent
Mechanism of action
A colloidal ferric iron-carbohydrate complex that is taken up by reticuloendothelial cells after intravenous administration, releasing iron for transferrin binding and haemoglobin synthesis. It is an intact complex rather than a simple sodium or gluconate salt.
Indications / reported uses
  • Treatment of iron-deficiency anaemia in adults and paediatric patients with chronic kidney disease receiving haemodialysis and supplemental epoetin therapy under the US FERRLECIT indication; not interchangeable with oral iron salts

Sources: US DailyMed — FERRLECIT (sodium ferric gluconate complex) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Intravenous ferric gluconate–carbohydrate complex; parenteral iron replacement agent

Mechanism of action

A colloidal ferric iron-carbohydrate complex that is taken up by reticuloendothelial cells after intravenous administration, releasing iron for transferrin binding and haemoglobin synthesis. It is an intact complex rather than a simple sodium or gluconate salt.

General use cases

  • Treatment of iron-deficiency anaemia in adults and paediatric patients with chronic kidney disease receiving haemodialysis and supplemental epoetin therapy under the US FERRLECIT indication; not interchangeable with oral iron salts

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Ferric Gluconate Environmental Risk Assessment (ERA) (the Ferric Gluconate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.